Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing first-in-class small molecule and antibody therapeutics across a diverse range of disorders for orphan and large-market indications. In partnership with physicians, regulators, and patients and their families, Omeros is focused on developing the most effective and safe therapeutics in serious diseases and disorders to improve or save the lives of patients who are suffering.
Together with its marketed ophthalmic drug OMIDRIA®, Omeros’ pipeline is led by narsoplimab (OMS721). Narsoplimab is a fully human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. Phase 3 clinical programs with narsoplimab are ongoing in hematopoietic stem cell-associated thrombotic microangiopathy, IgA nephropathy, and atypical hemolytic-uremic syndrome. Omeros’ pipeline includes additional large and small molecule complement inhibitors that are in development, as well as compounds being developed for addictions and other disorders of the central nervous system and immune-related diseases, including cancers.